FUSION PROTEINS COMPOSED OF AN INTERLEUKIN-2 MUTEIN AND TYPE I INTERFERON

The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG 1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the resulting molecules gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. The invention also relates to pharmaceutical compositions comprising the fusion proteins as an active ingredient. 本发明描述了基于细胞因子的融合蛋白，称为双细胞因子(BC)，具体地通过IL2激动剂突变蛋白与I型干扰素(IFN)的结合而形成，由突变人IgG1的Fc区和连接肽连接。IL2激动剂突变蛋白和I型IFN在双细胞因子结构中的组合为这些分子提供了令人惊讶的免疫调节特性，并且提供了比亲代细胞因子或它们的组合优越的治疗效果，这使它们成为用于治疗癌症的有吸引力的新颖分子。还描述了包含本专利的融合蛋白标的作为活性成分的药物组合物。